Refractory angiolymphoid hyperplasia with eosinophilia: Complete resolution with low dose thalidomide.
angiolymphoid hyperplasia with eosinophilia
refractory
symptomatic
thalidomide
treatment
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
27
04
2022
accepted:
17
05
2022
pubmed:
10
6
2022
medline:
1
12
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a difficult-to-treat and rare benign vascular proliferative condition which presents as painless, solitary, or multiple vascular papules or nodules in the head and neck area, with predilection for the ear. We report a case of ALHE that failed multiple therapeutic interventions but achieved complete resolution when treated with thalidomide.
Substances chimiques
Thalidomide
4Z8R6ORS6L
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
995-996Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Adler BL, Krausz AE, Minuti A, Silverberg JI, Lev-Tov H. Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): a systematic review. J Am Acad Dermatol. 2016;74(3):506-512.e11.
Rongioletti F, Cecchi F, Pastorino C, Scaparro M. Successful management of refractory angiolymphoid hyperplasia with eosinophilia with thalidomide. J Eur Acad Dermatol Venereol. 2016;30(3):527-529.
Mahmoud M, Walker SL. A systematic review of adverse drug reactions associated with thalidomide in the treatment of erythema nodosum leprosum. Lepr Rev. 2019;90:142-160.
Teo S, Resztak KE, Scheffler MA, et al. Thalidomide in the treatment of leprosy. Microbes Infect. 2002;4(11):1193-1202.
Savitha B, Sardana K, Kumari R, Khurana A, Sinha S, Sachdeva S. Case report: rapid response to low-dose thalidomide in a case of severe steroid recalcitrant erythema nodosum leprosum. Am J Trop Med Hyg. 2021;106(1):51-53.